RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)
January 03, 2020 00:00 ET
|
RadioMedix Inc.
Houston, Jan. 03, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National...
RadioMedix received $2.0 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers.
January 22, 2019 10:00 ET
|
RadioMedix Inc.
Houston (TX), Jan. 22, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been awarded a two-years, $2.0 M Phase II SBIR contract award by the NIH NCI...
RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate.
January 09, 2019 01:00 ET
|
RadioMedix Inc.
Houston, TX and St. Louis, MO, Jan. 09, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that their investigational diagnostic radiopharmaceutical,...
RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors
November 13, 2018 10:00 ET
|
RadioMedix Inc.
Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company)...
RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.
July 26, 2018 05:00 ET
|
RadioMedix Inc.
Houston (TX, USA) and Garching (Germany), July 26, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and ITM Isotopen Technologien München (ITM), a specialized radiopharmaceutical group of companies...
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors
January 10, 2018 05:00 ET
|
RadioMedix Inc.
Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...
RadioMedix Selected for National Cancer Institute’s Investor Initiatives and Presentation at BIO Investor Forum
October 17, 2017 08:08 ET
|
RadioMedix Inc.
Houston TX, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Houston, TX--RadioMedix Inc. a clinical-stage company, announced that it has been selected to present at the prestigious Biotechnology...
Extended partnership between Radiomedix INC and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America
October 11, 2017 06:00 ET
|
RadioMedix Inc.
Houston, TX, Oct. 11, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc, a biotechnological company, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer, and...
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
June 22, 2017 16:00 ET
|
RadioMedix Inc.
Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial evaluating the biodistribution...
First U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
February 06, 2017 06:00 ET
|
RadioMedix Inc.
Houston, TX; Los Angeles, CA, Feb. 06, 2017 (GLOBE NEWSWIRE) -- RadioMedix, Excel Diagnostics and Nuclear Oncology Center (EDNOC), and the Ahmanson Translational Imaging...